News | Left Atrial Appendage (LAA) Occluders | June 28, 2022

Acutus Medical Announces FDA Clearance, Commercial Launch of AcQCross Line Extension Compatible with Watchman Delivery System

Innovative Transseptal Access System Is First and Only to Feature Integrated Dilator and Needle to Reduce Exchanges 

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the commercial launch of an expanded suite of left-heart access products to now include the AcQCross Qx system for use with the TruSeal and FXDdelivery system for the Watchman LAAC Device.

June 27, 2022 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the commercial launch of an expanded suite of left-heart access products to now include the AcQCross Qx system for use with the TruSeal and FX delivery system for the Watchman LAAC Device

Gaining access to the left atrium requires physicians to cross the septum, a multi-step process that often involves the exchange of wires and needles while trying to achieve the proper angle and location on the septum. AcQCross is the first and only transseptal system engineered with an integrated needle and dilator to reduce these exchanges. US Left-atrial appendage closure procedures are expected to total over 50,000 in 2022, according to the Millennium Research Group. With this clearance, Acutus now offers sheath-compatible transseptal access devices that cover 409,000 electrophysiology and structural heart procedures in the US. 

“Crossing the septum at the proper location is important when doing any left-sided heart procedure, but it can be especially critical to the success of delivering Watchman to the left atrial appendage,” said Dr. Tom Waggoner, DO, FACC, FSCAI, FSVM, RPVI, Director, Structural Heart Program and Cardiovascular Research, Tucson Medical Center, Tucson, Arizona. “With AcQCross, I can easily reposition without withdrawing or exchanging needles or wires, so its new compatibility with Watchman has made my procedures much safer for my patients and far more efficient for me and my team.” 

AcQCross features an array of catheters that are length-, diameter- and tip-matched and designed to lock into the hub of market-leading sheaths used in the vast majority of left-heart procedures, including delivery of the Watchman. With the expanded product offering, physicians can utilize AcQCross with their preferred sheaths during virtually any left-heart access procedure. 

“The AcQCross system provides interventional cardiologists and electrophysiologists with unique benefits of broad compatibility with market-leading access sheaths while also enhancing procedure versatility and workflow,” said David Roman, interim Chief Executive Officer and Chief Financial Officer, Acutus Medical. “The expanded AcQCross product line allows us to bring this innovative technology to a wider range of procedure categories that should drive sustained growth in this portfolio.” 

AcQCross and its entire line of catheters are commercially available in the United States.  

For more information: www.acutusmedical.com/us/

 

Related content: 

Late-Breaking Study Results Reinforce Positive Real-World Outcomes with the WATCHMAN FLX LAAC Device 

Find more ACC22 content here 

PINNACLE FLX Study of New Watchman FLX LAA Occluder Meets Safety and Efficacy Endpoints  

First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes

Related Content

News | ACC

July 15, 2022 — The ACC has named Melvin R. Echols, MD, FACC, as its new Chief Diversity, Equity and Inclusion Officer ...

Home July 15, 2022
Home
Feature | ACC | By Melinda Taschetta-Millane

In April, the cardiology community converged face-to-face in Orlando for The American College of Cardiology’s (ACC22) ...

Home May 11, 2022
Home
News | ACC

April 12, 2022 – The American College of Cardiology (ACC) is establishing a new award in honor of Valentin Fuster, MD ...

Home April 12, 2022
Home
News | ACC
April 4, 2022 – Esperion presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL) ...
Home April 04, 2022
Home
News | ACC

April 3, 2022 — egnite, Inc., an advanced technology digital health company focused on providing artificial intelligence ...

Home April 03, 2022
Home
News | ACC

April 3, 2022 — A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath ...

Home April 03, 2022
Home
News | ACC

April 1, 2022 — Royal Philips, a global leader in health technology, announced new additions to its innovative ...

Home April 01, 2022
Home
News | ACC
March 31, 2022 – Healthcare AI solutions provider Aidoc will be delivering a live demonstration of its comprehensive AI ...
Home March 31, 2022
Home
News | ACC
March 31, 2022 – Experts from the Smidt Heart Institute at Cedars-Sinai, home to California’s top-ranked cardiology and ...
Home March 31, 2022
Home
News | ACC
March 31, 2022 – CathWorks has announced that the results of its most recent outcomes study on the CathWorks FFRangio ...
Home March 31, 2022
Home
Subscribe Now